TAT 2013


TAT, a leading oncology phase 1 meeting

TAT 2013, Paris, March 4-6 , 2013, will be the next meeting in the unique series "International Congress on Targeted Anticancer Therapies" (TAT), which is devoted to the most promising new molecularly-targeted cancer therapeutics. TAT meetings are leading oncology phase 1 meetings in Europe and a must-attend for clinical investigators, research scientists and drug development professionals in pharma, biotech and CROs:

• Focus on promising new agents and molecular targets that are - or soon will be - in phase 1 clinical study
• Clinical and translational research discussed extensively
• Educational introductions of target biology help "newcomers" understand the science behind new targets
• Excellent opportunities for young investigators to present for the first time in their career in a comfortable and overseeable setting
• Many of the world's leading phase 1 groups represented

Marriott Rive Gauche Hotel & Conference Center

Organizer: Congress by Design

4 Mar 2013